1. Marshall SE. (2004) Behcet's disease, Best Pract Res Clin Rheumatol.
18(3), 291-311.
2. Yazici H, Basaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y ve Dimitriyadis I. (1996) The ten-year mortality in Behcet's syndrome, Br J Rheumatol. 35(2), 139-41.
3. Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, Tunc R, Urgancioglu M ve Disci R. (2003) Prevalence of Behcet's disease in Istanbul, Turkey, Int J Dermatol. 42(10), 803-6.
4. Sakane T, Takeno M, Suzuki N ve Inaba G. (1999) Behcet's disease, N Engl J Med. 341(17), 1284-91.
5. Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M ve Touitou I. (1999) Familial aggregation in Behcet's disease: high frequency in siblings and parents of pediatric probands, J Pediatr. 135(1), 89-93.
6. Lee ES, Lee S, Bang D ve S. S. (1997) Herpes simplex virus detection by polymerase chain reaction in intestinal ulcer of patients with Behçet’s disease. In: M Hamza, ed. Proceedings of the 7 th International Conference on Behçet’s Disease. Tunis, Tunisia: Pub Adhona,71-4.
7. International_Study_Group_for_Behcet's_Disease. (1990) Criteria for diagnosis of Behcet's disease. , Lancet. 335(8697), 1078-80.
8. Wang B, Wang J, Huang SQ, Su HH ve Zhou SF. (2009) Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance, Curr Drug Metab. 10(7), 781-834.
9. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E ve Dahl ML. (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype, Clin Pharmacol Ther.
71(1), 89-98.
10. Yasar U, Dahl ML, Christensen M ve Eliasson E. (2002) Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity, Br J Clin Pharmacol. 54(2), 183-5.
11. Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, Hishida A, Watanabe H ve Umemura K. (2009) [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole, Aliment Pharmacol Ther. 30(3), 294-300.
12. Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, Uslu N, Bozkurt A, Yuce A ve Yasar U. (2012) Evaluation of lansoprazole as a
probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood, Eur J Clin Pharmacol. 68(5), 629-36.
13. Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, Gottesman MM ve Pastan I. (1986) Localization of multidrug resistance-associated DNA sequences to human chromosome 7, Somat Cell Mol Genet. 12(4), 415-20.
14. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I ve Bozkurt A. (2005) Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists, Clin Pharmacol Ther.
78(6), 619-26.
15. Aynacioglu AS, Bozkurt A, Nacak M, Kortunay S, Tunc R, Dincel A ve Kayaalp SO. (2001) N-acetyltransferase polymorphism in patients with Behcet's disease, Eur J Clin Pharmacol. 57(9), 659-62.
16. Yen JH, Tsai WC, Lin CH, Ou TT, Hu CJ ve Liu HW. (2004) Cytochrome P450 1A1 and manganese superoxide dismutase gene polymorphisms in Behcet's disease, J Rheumatol. 31(4), 736-40.
17. Tursen U, Tamer L, Api H, Yildirim H, Baz K, Ikizoglu G ve Atik U. (2007) Cytochrome P450 polymorphisms in patients with Behcet's disease, Int J Dermatol. 46(2), 153-6.
18. Hellden A, Bergman U, Engstrom Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlof I, Ramsjo M ve Bertilsson L. (2010) Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9, Eur J Clin Pharmacol. 66(8), 791-5.
19. Rustemoglu A, Gul U, Gumus-Akay G, Gonul M, Yigit S, Bozkurt N, Karadag A, Piskin E, Sunguroglu A ve Kadikiran A. (2012) MDR1 gene polymorphisms may be associated with Behcet's disease and its colchicum treatment response, Gene. 505(2), 333-9.
20. Behçet H. (1937) Uber rezidivierende Aphtose, durch ein virus verursachte Geschwure am Mund, amAuge und an den genitalien, Dermatol Wochenschr. 105 1152-7.
21. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O ve Valente J. (2009) Behcet's disease--a contemporary review, J Autoimmun. 32(3-4), 178-88.
22. Kural-Seyahi E, Fresko I ve Seyahi N. (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center, Medicine (Baltimore). 8260-76.
23. Feigenbaum A. (1956) Description of Behcet's syndrome in the Hippocratic third book of endemic diseases, Br J Ophthalmol. 40(6), 355-7.
24. Cheng TO. (2001) Some historical notes on Behcet's disease, Chest. 119(2), 667-8.
25. Behçet H. (1942) Trisymptomes Complex, veya Syndrom yahut Morbus Behçet Nasıl Tesbit Edilmiştir., Deri Hastalıkları ve Frengi Kliniği Arşivi. 9(53-54), 2663-2673.
26. Behçet H. (1937) Ağız ve tenasül uzuvlarında husule gelen aftöz tegayyürlerle ayni zamanda görünen virutik olması muhtemel teşevvüşler üzerine mülahazalar ve mihraki intan hakkında şüpheler, Deri Hast Frengi Klin Arş. 41369-1378.
27. Tüzün Y. (2006) Hulusi Behçet MD February 20, 1889 to March 8, 1948, Clinics in Dermatology. 24548-550.
28. James DG. (1986) Silk Route disease, Postgrad Med J. 62(725), 151-3.
29. Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L ve Zouboulis CC.
(2006) Epidemiology and clinical manifestations of Adamantiades -Behcet disease in Germany -- current pathogenetic concepts and therapeutic possibilities, J Dtsch Dermatol Ges. 4(1), 49-64; quiz 65-6.
30. Zouboulis CC. (1999) Epidemiology of Adamantiades-Behcet's disease, Ann Med Interne (Paris). 150(6), 488-98.
31. Tuzun Y, Yurdakul S, Cem Mat M, Ozyazgan Y, Hamuryudan V, Tuzun B ve Yazici H. (1996) Epidemiology of Behcet's syndrome in Turkey, Int J Dermatol. 35(9), 618-20.
32. Hamuryudan V, Yurdakul S ve Yazici H. (2005) Behçet Hastalığı, Türkiye Klinikleri J Int Med Sci. 1(25), 1-72.
33. Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M ve T. S. (1993) Recent epidemiological features of Behçet’s disease in Japan. In: Godeau P, Wechsler (eds): Behçet’s disease, Excerpta Medica, Amsterdam,145-51.
34. Jankowski J, Crombie I ve Jankowski R. (1992) Behcet's syndrome in Scotland, Postgrad Med J. 68(801), 566-70.
35. Al-Rawi ZS ve Neda AH. (2003) Prevalence of Behcet's disease among Iraqis, Adv Exp Med Biol. 52837-41.
36. Gonzalez-Gay MA, Garcia-Porrua C, Branas F, Lopez-Lazaro L ve Olivieri I.
(2000) Epidemiologic and clinical aspects of Behcet's disease in a defined area of Northwestern Spain, 1988-1997, J Rheumatol. 27(3), 703-7.
37. Evereklioglu C. (2005) Current concepts in the etiology and treatment of Behcet disease, Surv Ophthalmol. 50(4), 297-350.
38. Sakane T, Suzuki N ve Nagafuchi H. (1997) Etiopathology of Behcet's disease: immunological aspects, Yonsei Med J. 38(6), 350-8.
39. Arayssi T ve Hamdan A. (2004) New insights into the pathogenesis and therapy of Behcet's disease, Curr Opin Pharmacol. 4(2), 183-8.
40. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A ve Aizawa M. (1982) Close association of HLA-Bw51 with Behcet's disease, Arch Ophthalmol.
100(9), 1455-8.
41. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE ve Jewell DP. (2003) Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms?, Arthritis Rheum.
48(3), 807-13.
42. Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, Kaklamani E, Accorinti M, Pivetti-Pezzi P, Ohno S ve Inoko H. (2000) Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations, Invest Ophthalmol Vis Sci. 41(12), 3702-8.
43. Cohen R, Metzger S, Nahir M ve Chajek-Shaul T. (2002) Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel, Ann Rheum Dis. 61(2), 157-60.
44. Salvarani C, Boiardi L, Mantovani V, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Molinotti C, Govoni M, Trotta F, Filippini D, Paolazzi G ve Viggiani M. (2001) Association of MICA alleles and HLA-B51 in Italian patients with Behcet's disease, J Rheumatol. 28(8), 1867-70.
45. Mizuki N, Yabuki K, Ota M, Verity D, Katsuyama Y, Ando H, Onari K, Goto K, Imagawa Y, Mandanat W, Fayyad F, Stanford M, Ohno S ve Inoko H. (2001) Microsatellite mapping of a susceptible locus within the HLA region for Behcet's disease using Jordanian patients, Hum Immunol. 62(2), 186-90.
46. Choukri F, Chakib A, Himmich H, Hue S ve Caillat-Zucman S. (2001) HLA-B*51 and B*15 alleles confer predisposition to Behcet's disease in Moroccan patients, Hum Immunol. 62(2), 180-5.
47. Gonzalez-Escribano MF, Rodriguez MR, Walter K, Sanchez-Roman J, Garcia-Lozano JR ve Nunez-Roldan A. (1998) Association of HLA-B51 subtypes and Behcet's disease in Spain, Tissue Antigens. 52(1), 78-80.
48. Mizuki N, Yabuki K, Ota M, Katsuyama Y, Ando H, Nomura E, Funakoshi K, Davatchi F, Chams H, Nikbin B, Ghaderi AA, Ohno S ve Inoko H. (2002) Analysis of microsatellite polymorphism around the HLA-B locus in Iranian patients with Behcet's disease, Tissue Antigens. 60(5), 396-9.
49. Park SH, Park KS, Seo YI, Min DJ, Kim WU, Kim TG, Cho CS, Mok JW, Park KS ve Kim HY. (2002) Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease, J Korean Med Sci. 17(3), 366-70.
50. Kotter I, Gunaydin I, Stubiger N, Yazici H, Fresko I, Zouboulis CC, Adler Y, Steiert I, Kurz B, Wernet D, Braun B ve Muller CA. (2001) Comparative analysis of the association of HLA-B*51 suballeles with Behcet's disease in patients of German and Turkish origin, Tissue Antigens. 58(3), 166-70.
51. Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G ve Rammensee HG. (1995) Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behcet's disease, Int Immunol. 7(2), 223-8.
52. Gul A, Uyar FA, Inanc M, Ocal L, Tugal-Tutkun I, Aral O, Konice M ve Saruhan-Direskeneli G. (2001) Lack of association of HLA-B*51 with a severe disease course in Behcet's disease, Rheumatology (Oxford). 40(6), 668-72.
53. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H ve Sakane T. (1995) Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice, Arthritis Rheum. 38(3), 426-33.
54. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B ve Kaklamanis P. (2003) Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece, Clin Exp Rheumatol. 21(4 Suppl 30), S19-26.
55. Direskeneli H. (2001) Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51, Ann Rheum Dis. 60(11), 996-1002.
56. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL ve Spies T. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress -inducible MICA, Science. 285(5428), 727-9.
57. Kamoun M, Chelbi H, Houman MH, Lacheb J ve Hamzaoui K. (2007) Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease, Hum Immunol. 68(3), 201-5.
58. Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E ve Yegin O. (2006) TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease, Br J Dermatol. 155(2), 350-6.
59. Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, Alpsoy E ve Yegin O. (2008) Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behcet's disease, J Eur Acad Dermatol Venereol. 22(8), 950-7.
60. Krause I ve Weinberger A. (2008) Behcet's disease, Curr Opin Rheumatol.
20(1), 82-7.
61. Wallace GR, Verity DH, Delamaine LJ, Ohno S, Inoko H, Ota M, Mizuki N, Yabuki K, Kondiatis E, Stephens HA, Madanat W, Kanawati CA, Stanford MR ve Vaughan RW. (1999) MIC-A allele profiles and HLA class I associations in Behcet's disease, Immunogenetics. 49(7-8), 613-7.
62. Mizuki N, Inoko H ve Ohno S. (1997) Molecular genetics (HLA) of Behc et's disease, Yonsei Med J. 38(6), 333-49.
63. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, Nakamura S, Bahram S, Ohno S ve Inoko H. (1999) Association analysis between the
MIC-A and HLA-B alleles in Japanese patients with Behcet's disease, Arthritis Rheum. 42(9), 1961-6.
64. Hirohata S ve Kikuchi H. (2003) Behcet's disease, Arthritis Res Ther. 5(3), 139-46.
65. Coskun M, Bacanli A, Sallakci N, Alpsoy E, Yavuzer U ve Yegin O. (2005) Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet's disease, Exp Dermatol. 14(2), 124-9.
66. Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M ve Gul A. (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease, Rheumatology (Oxford). 42(7), 860-4.
67. Nothwang HG, Strahm B, Denich D, Kubler M, Schwabe J, Gingrich JC, Jauch A, Cox A, Nicklin MJ, Kurnit DM ve Hildebrandt F. (1997) Molecular cloning of the interleukin-1 gene cluster: construction of an integrated YAC/PAC contig and a partial transcriptional map in the region of chromosome 2q13, Genomics. 41(3), 370-8.
68. Ozcimen AA, Dilek K, Bingol U, Saricaoglu H, Sarandol A, Taskapilioglu O, Yurtkuran M, Yurtkuran MA ve Oral HB. (2011) IL-1 cluster gene polymorphisms in Turkish patients with Behcet's disease, Int J Immunogenet. 38(4), 295-301.
69. Gul A, Ozbek U, Ozturk C, Inanc M, Konice M ve Ozcelik T. (1996) Coagulation factor V gene mutation increases the risk of venous thrombosis in behcet's disease, Br J Rheumatol. 35(11), 1178-80.
70. Toydemir PB, Elhan AH, Tukun A, Toydemir R, Gurler A, Tuzuner A ve Bokesoy I. (2000) Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothombin gene G20210A mutations on deep venous thrombogenesis in Behcet's disease, J Rheumatol. 27(12), 2849-54.
71. Mammo L, Al-Dalaan A, Bahabri SS ve Saour JN. (1997) Association of factor V Leiden with Behcet's disease, J Rheumatol. 24(11), 2196-8.
72. Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, Kanawati CA, Ayesh I, Stanford MR ve Wallace GR. (1999) Factor V Leiden mutation is associated with ocular involvement in Behcet disease, Am J Ophthalmol. 128(3), 352-6.
73. Oner AF, Gurgey A, Gurler A ve Mesci L. (1998) Factor V Leiden mutation in patients with Behcet's disease, J Rheumatol. 25(3), 496-8.
74. Gurgey A, Balta G ve Boyvat A. (2003) Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease, Blood Coagul Fibrinolysis. 14(2), 121-4.
75. Batioglu F, Atmaca LS, Karabulut HG ve Beyza Sayin D. (2003) Factor V Leiden and prothrombin gene G20210A mutations in ocular Behcet disease, Acta Ophthalmol Scand. 81(3), 283-5.
76. Nejentsev S, Guja C, McCormack R, Cooper J, Howson JM, Nutland S, Rance H, Walker N, Undlien D, Ronningen KS, Tuomilehto-Wolf E, Tuomilehto J, Ionescu-Tirgoviste C, Gale EA, Bingley PJ, Gillespie KM, Savage DA, Carson DJ, Patterson CC, Maxwell AP ve Todd JA. (2003) Association of intercellular adhesion molecule-1 gene with type 1 diabetes, Lancet. 362(9397), 1723-4.
77. Kretowski A, Wawrusiewicz N, Mironczuk K, Mysliwiec J, Kretowska M ve Kinalska I. (2003) Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease, J Clin Endocrinol Metab. 88(10), 4945-9.
78. Cournu-Rebeix I, Genin E, Lesca G, Azoulay-Cayla A, Tubridy N, Noe E, Clanet M, Edan G, Clerget-Darpoux F, Semana G ve Fontaine B. (2003) Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis, Genes Immun. 4(7), 518-23.
79. Matsuzawa J, Sugimura K, Matsuda Y, Takazoe M, Ishizuka K, Mochizuki T, Seki SS, Yoneyama O, Bannnai H, Suzuki K, Honma T ve Asakura H. (2003) Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population, Gut. 52(1), 75-8.
80. Aydintug AO, Tokgoz G, Ozoran K, Duzgun N, Gurler A ve Tutkak H. (1995) Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behcet's disease, Rheumatol Int. 15(2), 75-8.
81. Verity DH, Wallace GR, Seed PT, Kanawati CA, Ayesh I, Holland-Gladwish J ve Stanford MR. (1998) Soluble adhesion molecules in Behcet's disease, Ocul Immunol Inflamm. 6(2), 81-92.
82. Hamzaoui A, Hamzaoui K, Chabbou A ve Ayed K. (1995) Circulating intercellular adhesion molecules in blood and bronchoalveolar lavage in Behcet's disease, Mediators Inflamm. 4(5), 355-8.
83. Saruhan-Direskeneli G, Uyar FA, Cefle A, Onder SC, Eksioglu-Demiralp E, Kamali S, Inanc M, Ocal L ve Gul A. (2004) Expression of KIR and C-type lectin receptors in Behcet's disease, Rheumatology (Oxford). 43(4), 423-7.
84. Salvarani C, Boiardi L, Casali B, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Govoni M, Trotta F, Filippini D, Paolazzi G, Nicoli D, Farnetti E ve Macchioni P. (2002) Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease, J Rheumatol. 29(3), 535-40.
85. Buldanlioglu S, Turkmen S, Ayabakan HB, Yenice N, Vardar M, Dogan S ve Mercan E. (2005) Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behcet's disease, Br J Dermatol.
153(3), 526-30.
86. Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E ve Yegin O. (2005) CTLA-4 gene 49A/G polymorphism in Turkish patients with Behcet's disease, Clin Exp Dermatol. 30(5), 546-50.
87. Du L, Yang P, Hou S, Zhou H ve Kijlstra A. (2009) No association of CTLA-4 polymorphisms with susceptibility to Behcet disease, Br J Ophthalmol.
93(10), 1378-81.
88. Lehner T. (1997) The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease, Int Rev Immunol. 14(1), 21-32.
89. Sohn S, Lee ES, Bang D ve Lee S. (1998) Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice, Eur J Dermatol. 8(1), 21-3.
90. Baskan EB, Yilmaz E, Saricaoglu H, Alkan G, Ercan I, Mistik R, Adim SB, Goral G, Dilek K ve Tunali S. (2007) Detection of parvovirus B19 DNA in the lesional skin of patients with Behcet's disease, Clin Exp Dermatol. 32(2), 186-90.
91. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y ve Celik I. (1996) The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial, Arthritis Rheum. 39(12), 2062-5.
92. Yoshikawa K, Kotake S ve Matsuda H. (1996) [Behcet's disease and streptococcal antigens], Nihon Ganka Gakkai Zasshi. 100(3), 173-80.
93. Yoshikawa H, Kotake S, Sasamoto Y, Ohno S ve Matsuda H. (1990) Close association of Streptococcus sangius and Behçet’s disease, Nippon Ganka Gakkai Zasshi Dec. 95(12), 1261-7.
94. Cakmak SK, Cakmak A, Gul U, Sulaimanov M, Bingol P ve Hazinedaroglu MS. (2009) Upper gastrointestinal abnormalities and Helicobacter pylori in Behcet's disease, Int J Dermatol. 48(11), 1174-6.
95. Onen F, Tuncer D, Akar S, Birlik M ve Akkoc N. (2003) Seroprevalence of Borrelia burgdorferi in patients with Behcet's disease, Rheumatol Int. 23(6), 289-93.
96. di Meo N, Quaranta L, Crisman G ve Trevisan G. (2009) Adamantiades Behcet Disease triggered by a tick bite and or borrelia infection, J Eur Acad Dermatol Venereol. 23(10), 1198-9.
97. Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, Vaughan R ve Lehner T. (1993) T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease, J Immunol. 151(4), 2273-82.
98. Vaiopoulos G, Lakatos PL, Papp M, Kaklamanis F, Economou E, Zevgolis V, Sourdis J ve Konstantopoulos K. (2011) Serum anti-Saccharomyces cerevisiae antibodies in Greek patients with Behcet's disease, Yonsei Med J.
52(2), 347-50.
99. Filik L ve Biyikoglu I. (2008) Differentiation of Behcet's disease from inflammatory bowel diseases: anti-Saccharomyces cerevisiae antibody and anti-neutrophilic cytoplasmic antibody, World J Gastroenterol. 14(47), 7271.
100. Choi CH, Kim TI, Kim BC, Shin SJ, Lee SK, Kim WH ve Kim HS. (2006) Anti-Saccharomyces cerevisiae antibody in intestinal Behcet's disease patients:
relation to clinical course, Dis Colon Rectum. 49(12), 1849-59.
101. Ritossa F. (1996) Discovery of the heat shock response, Cell Stress Chaperones. 1(2), 97-8.
102. Direskeneli H, Eksioglu-Demiralp E, Yavuz S, Ergun T, Shinnick T, Lehner T ve Akoglu T. (2000) T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behcet's disease, J Rheumatol.
27(3), 708-13.
103. Wheeler DS ve Wong HR. (2007) Heat shock response and acute lung injury, Free Radic Biol Med. 42(1), 1-14.
104. Ergun T, Ince U, Eksioglu-Demiralp E, Direskeneli H, Gurbuz O, Gurses L, Aker F ve Akoglu T. (2001) HSP 60 expression in mucocutaneous lesions of Behcet's disease, J Am Acad Dermatol. 45(6), 904-9.
105. Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, Yamamoto S ve Sakane T. (1997) Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan, Clin Exp Immunol. 108(2), 204-12.
106. Direskeneli H ve Saruhan-Direskeneli G. (2003) The role of heat shock proteins in Behcet's disease, Clin Exp Rheumatol. 21(4 Suppl 30), S44-8.
107. Yamamoto JH, Minami M, Inaba G, Masuda K ve Mochizuki M. (1993) Cellular autoimmunity to retinal specific antigens in patients with Behcet's disease, Br J Ophthalmol. 77(9), 584-9.
108. Takeuchi M, Usui Y, Okunuki Y, Zhang L, Ma J, Yamakawa N, Hattori T, Kezuka T, Sakai J ve Goto H. (2010) Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis, Invest Ophthalmol Vis Sci. 51(6), 3067-75.
109. Hamzaoui K, Mili Boussen E, Hamzaoui A, Ouertani A, Chabbou A ve Ayed K. (1998) Cellular autoimmunity to retinal specific antigens in Behcet's disease, Tunis Med. 76(4), 66-70.
110. Direskeneli H, Keser G, D'Cruz D, Khamashta MA, Akoglu T, Yazici H, Yurdakul S, Hamuryudan V, Ozgun S, Goral AJ ve et al. (1995) Anti-endothelial cell antibodies, Anti-endothelial proliferation and von Willebrand factor antigen in Behcet's disease, Clin Rheumatol. 14(1), 55-61.
111. Zheng WJ, Zhao Y, Tang FL ve Dong Y. (2005) [A study of antiendothelial cell antibodies in Behcet's disease], Zhonghua Nei Ke Za Zhi. 44(12), 910-3.
112. Aydintug AO, Tokgoz G, D'Cruz DP, Gurler A, Cervera R, Duzgun N, Atmaca LS, Khamashta MA ve Hughes GR. (1993) Antibodies to endothelial cells in patients with Behcet's disease, Clin Immunol Immunopathol. 67(2), 157-62.
113. Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY ve Nussenblatt RB. (2005) Alpha tropomyosin as a self-antigen in patients with Behcet's disease, Clin Exp Immunol. 140(2), 368-75.
114. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M ve Capo C. (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects, J Rheumatol. 20(9), 1544-9.
115. Evereklioglu C, Er H, Turkoz Y ve Cekmen M. (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease, Mediators Inflamm. 11(2), 87-93.
116. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M ve Ayed K.
(2002) Cytokine profile in Behcet's disease patients. Relationship with disease activity, Scand J Rheumatol. 31(4), 205-10.
117. Miletic M, Stojanovic R, Pajic O, Bugarski D, Mojsilovic S, Cokic V ve Milenkovic P. (2012) Serum interleukin-17 & nitric oxide levels in patients with primary Sjogren's syndrome, Indian J Med Res. 135(4), 513-9.
118. Yilmaz M, Kendirli SG, Altintas D, Bingol G ve Antmen B. (2001) Cytokine levels in serum of patients with juvenile rheumatoid arthritis, Clin Rheumatol.
20(1), 30-5.
119. Hamzaoui K, Hamzaoui A, Kahan A, Hamza M, Chabbou A ve Ayed K.
(1992) Interleukin-6 in peripheral blood and inflammatory sites in Behcet's disease, Mediators Inflamm. 1(4), 281-5.
120. Yamakawa Y, Sugita Y, Nagatani T, Takahashi S, Yamakawa T, Tanaka S, Nakamura S, Ohno S, Sekihara H, Okuda K ve Nakajima H. (1996) Interleukin-6 (IL-6) in patients with Behcet's disease, J Dermatol Sci. 11(3), 189-95.
121. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A ve Hashimoto T. (1997) Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome, Clin Immunol Immunopathol. 82(1), 12-7.
122. Wang CR, Chuang CY ve Chen CY. (1992) Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behcet's syndrome, Clin Exp Rheumatol. 10(6), 599-602.
123. Davatchi F, Shahram F, Chams C, Chams H ve Nadji A. (2005) Behçet’s disease, Acta Medica Iranica. 43(4)233-242.
124. Chajek T ve Fainaru M. (1975) Behcet's disease. Report of 41 cases and a review of the literature, Medicine (Baltimore). 54(3), 179-96.
125. Montenegro V, Carlotto De Abreu A, Schaimberg C ve Roberto Gonçalves C. (1998) Behcet’s disease in 81 Brazilian patients, 8th International Conference on Behcet’s Disease.Reggio Emilia (Italy),Abstract P143.
126. Bang D, Yoon KH, Chung HG, Choi EH, Lee ES ve Lee S. (1997) Yonsei Med J. 38 428-436.
127. Assaad-Khalil SH, Kamel FA ve Ismail E A. (1997) Starting regional registry forpatients with Behcet’s Disease in North-West Nile Delta region in Egypt. In Behcet’s Disease Hamza M. (ed), Tunisia, Pub Adhoua,173-176.
128. Madanat W, Fayyad F, Zureikat H, Verity D, Narr J, Vaughan R ve Stanford M. (2000) Influence of sex on Behcet’s Disease in Jordan. In: Bang D, Lee E, Lee S, eds. Behcet's Disease, Seoul: Design Mecca Publishing,90-93.
129. Dong Yi, Ming Qiu Xiao, Zhang Nai Zheng, Li Cui Hai ve Wu Qi Yan. (1991) Testing different diagnostic criteria of Behcet’s syndrome in Chinese patients, In Behcet’s Disease Basic and Clinical Aspects, O’Duffy JD and Kokmen E (eds), New York, Marcel Decker Inc,55-99.
130. Valesini G, Pivetti Pezzi P, Catarinelli G, Accorinti M ve Priori R. (1991) Clinical manifestations of Behcet’s disease in Italy: study of 155 patients at Rome university, In Behcet’s Disease Basic and Clinical Aspects, O’Duffy JD and Kokmen E (eds), New York, Marcel Decker Inc,279-289.
131. Gurler A, Boyvat A ve Tursen U. (1997) Clinical manifestations of Behcet's disease: an analysis of 2147 patients, Yonsei Med J. 38(6), 423-7.
132. Roux H, Richard P, Aarrighi A ve Bergaoui N. (1989) Autochtone Behcet's disease.A propos of 73 cases., Rev Rhum 56:383-388.
133. al-Dalaan AN, al Balaa SR, el Ramahi K, al-Kawi Z, Bohlega S, Bahabri S ve al Janadi MA. (1994) Behcet's disease in Saudi Arabia, J Rheumatol. 21(4), 658-61.
134. Yurdakul S ve Yazici H. (2008) Behcet's syndrome, Best Pract Res Clin Rheumatol. 22(5), 793-809.
135. Alpsoy E, Zouboulis CC ve Ehrlich GE. (2007) Mucocutaneous lesions of Behcet's disease, Yonsei Med J. 48(4), 573-85.
136. Bang D, Hur W, Lee ES ve Lee S. (1995) Prognosis and clinical relevance of recurrent oral ulceration in Behcet's disease, J Dermatol. 22(12), 926-9.
137. Shimizu S, Chen KR, Ikemoto K ve Han-Yaku H. (1998) Abrupt onset of severe Behçet’s disease: preceding oral ulceration is not essential for diagnosis., Br J Dermatol. 139(1)160-1.
138. Shahram F, Nadji A, Jamshidi AR, Chams H, Chams C, Shafaie N, Akbarian M, Gharibdoost F ve Davatchi F. (2004) Behcet’s Disease in Iran, analysis of 5059 cases, Arch Iranian Med. 7:9-14.
139. Alekberova Z, Madanat W, Prokaeva T, Yermakova N ve Poljanskaja I.
(1993) Clinical andgenetic features of 35 patients with Behcet’s Disease from Commonwealth Independent States. In Behcet’s Disease, Godeau P and Wechsler B (eds), Amsterdam, Elsevier Science Publishers B.V.,171-174.
140. Kasifoglu T ve Korkmaz C. (2012) Romatoloji Atlası,97.
141. Kontogiannis V ve Powell RJ. (2000) Behcet's disease, Postgrad Med J.
76(900), 629-37.
142. Gürler A, Ertan C, Kazeruni H ve Sayman N. (1992) Ankara Üniversitesi Tıp Fakültesi Behçet Hastalığı Merkezinde izlemekte olduğumuz 912 rezidivan aftöz stomatitli olguların klinik gözlemleri, Prof. Dr. A. Lütfi Tat Sempozyumu Kitabı,298-308.
143. Al-Otaibi LM, Porter SR ve Poate TW. (2005) Behcet's disease: a review, J Dent Res. 84(3), 209-22.
144. Yazıcı H, Fresko I, Tunç R ve Melikoglu M. (2002) Behçet’s syndrome:
pathogenesis, clinical manifestations and treatment.In:Ball GV, Bridges SL, editors. , Vasculitis. Oxford: University Press,406-32.
145. Nazzaro P. (1966) Cutaneous manifestations of Behçet's disease, In:
International Symposium on Behçet's Disease in Rome. Monacelli M, Nazzaro P, editors. Karger: Basel,1-24.
146. Kasifoglu T ve Korkmaz C. (2012) Romatoloji atlası,99.
147. Dunlop E. (1979) Genital and other manifestations of Behçet's disease seen in venereological clinical practice, In: Behçet's syndrome: clinical and immunological features. Lehner T, Barnes G, editors. Academic Press ,159-175.
148. Lin P ve Liang G. (2006) Behcet disease: recommendation for clinical management of mucocutaneous lesions, J Clin Rheumatol. 12(6), 282-6.
149. E.Alpsoy. (2003) Behçet hastalığının deri ve mukoza belirtileri., Türkderm 37(2), 92-99.
150. Kasifoglu T ve Korkmaz C. (2012) Romatoloji Atlası,100.
151. Tüzün Y, Fresko İ, Mat MC, Özyazgan Y ve Hamuryudan V. (2008) Behçet Sendromu, Ed; Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL.
3.baskı, Nobel Tıp Kitapevleri, İstanbul,913-928.
152. Demircioğlu FF, Böke E, Demircin M, Dağsali S ve Küçükali T. (1989) Abdominal aortic aneurysm with inferior vena cava obstruction: case report., Angiology. 40 227-232.
153. Kansu E, Özer FL ve Akalin E. (1972) Behçet syndrome with obstruction of the vena cava, Q J Med. 41 151-168.
154. Ergun T, Gurbuz O, Dogusoy G, Mat C ve Yazici H. (1998) Histopathologic features of the spontaneous pustular lesions of Behcet's syndrome, Int J Dermatol. 37(3), 194-6.
155. Jorizzo JL, Abernethy JL ve White WL. (1995) Mucocutaneous criteria fort the diagnosis of Behçet’s disease: an analysis of clinicophatologic data from multipl international centers., J Am Acad Dermatol. 32 968-76.
156. Azizlerli G, Ozarmagan G, Ovul C, Sarica R ve Mustafa SO. (1992) A new kind of skin lesion in Behcet's disease: extragenital ulcerations, Acta Derm Venereol. 72(4), 286.
157. Saylan T, Mat C, Fresko I ve Melikoglu M. (1999) Behcet's disease in the Middle East, Clin Dermatol. 17(2), 209-23; discussion 105-6.
158. Kasifoglu T ve Korkmaz C. (2012) Romatoloji Atlası,101.
159. Akmaz O, Erel A ve Gurer MA. (2000) Comparison of histopathologic and clinical evaluations of pathergy test in Behcet's disease, Int J Dermatol.
39(2), 121-5.
160. Tüzün Y, Serdaroğlu S ve Aydemir EH. (1993) Paterji fenomeni., Dermatolojide gelişmeler-2 İstanbul 96-105.
161. Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S ve Muftuoglu A. (1984) A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease, Ann Rheum Dis. 43(1), 74-5.
162. Kim JW, Park JH, Lee D, Hwang SW ve Park SW. (2007) Vegetative pyoderma gangrenosum in Behcet's disease, Acta Derm Venereol. 87(4), 365-7.
163. Lee ES, Bang D ve Lee S. (1997) Dermatologic manifestation of Behcet's disease, Yonsei Med J. 38(6), 380-9.
164. Kasifoglu T ve Korkmaz C. (2012) Romatoloji Atlası,103.
165. Calamia KT, Mazlumzadeh M, Balbanova M, Bagheri M ve O’Duffy JD.
(2000) Clinical characteristics of United States patients with Behcet’s disease. In: Bang D, Lee E, Lee S, eds. Behcet's Disease. Seoul, Design Mecca Publishing,48-51.
166. Michelson JB ve Friedlaender MH. (1990) Behcet's disease, Int Ophthalmol Clin. 30(4), 271-8.
167. Benezra D ve Cohen E. (1986) Treatment and visual prognosis in Behcet's disease, Br J Ophthalmol. 70(8), 589-92.
168. Yurdakul SY, H. Tuzun, Y. Pazarli, H. Yalcin, B. Altac, M. Ozyazgan, Y.
Tuzuner, N. Muftuoglu, A. (1983) The arthritis of Behcet's disease: a prospective study, Ann Rheum Dis. 42(5), 505-15.
169. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, Yazganoglu KD, Disci R, Erzengin D ve Azizlerli G. (2006) Vascular involvement in Behcet's disease:
a retrospective analysis of 2319 cases, Int J Dermatol. 45(8), 919-21.
170. Yazici H, Fresko I ve Yurdakul S. (2007) Behcet's syndrome: disease manifestations, management, and advances in treatment, Nat Clin Pract Rheumatol. 3(3), 148-55.
171. Espinosa G, Cervera R, Reverter JC, Tassies D, Font J ve Ingelmo M.
(2002) Vascular involvement in Behcet's disease, Isr Med Assoc J. 4(8), 614-6.
172. Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Celik I ve Calguneri M.
(2002) Pathological haemostasis and "prothrombotic state" in Behcet's disease, Thromb Res. 105(2), 125-33.
173. Kaklamani VG, Vaiopoulos G ve Kaklamanis PG. (1998) Behcet's Disease, Semin Arthritis Rheum. 27(4), 197-217.
174. Akman-Demir G, Serdaroglu P ve B. T. (1999) Clinical patterns of neurological involvement in Behçet’s Disease Evaluation of 200 patients. , The Neuro-Behçet Study Group Brain 1222183-94.
175. Ghate JV ve Jorizzo JL. (1999) Behcet's disease and complex aphthosis, J Am Acad Dermatol. 40(1), 1-18; quiz 19-20.
176. Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V ve Yazici H. (1996) Gastrointestinal involvement in Behcet's syndrome: a controlled study, Ann Rheum Dis. 55(3), 208-10.
177. Hassard PV, Binder SW, Nelson V ve Vasiliauskas EA. (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report, Gastroenterology. 120(4), 995-9.
178. Bayraktar Y, Ozaslan E ve Van Thiel DH. (2000) Gastrointestinal manifestations of Behcet's disease, J Clin Gastroenterol. 30(2), 144-54.
179. Uçan E.S, Kıter G, Abadoglu O, Karlıkaya C, Akoglu S ve Bayındır U.
Thoracic manifestations of Behçet’s disease: Reports of the Turkish authors., Turkish Respiratory Journal 2(2), 39-44.
180. Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N ve Salvarani C.
(2005) Behcet's disease and cardiovascular involvement, Lupus. 14(9), 723-6.
181. Gurgun C, Ercan E, Ceyhan C, Yavuzgil O, Zoghi M, Aksu K, Cinar CS ve Turkoglu C. (2002) Cardiovascular involvement in Behcet's disease, Jpn Heart J. 43(4), 389-98.
182. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR ve Ozen S. (2002) Renal Behcet's disease: a cumulative analysis, Semin Arthritis Rheum.
31(5), 317-37.
183. Cho YH, Jung J, Lee KH, Bang D, Lee ES ve Lee S. (2003) Clinical features of patients with Behcet's disease and epididymitis, J Urol. 170(4 Pt 1), 1231-3.
184. Mason RM ve Barnes CG. (1969) Behcet's syndrome with arthritis, Ann Rheum Dis. 28(2), 95-103.
185. O’duffy J. (1974) Suggested criteria for diagnosis of Behçet’s disease, J Rheumatol 32(18).
186. Zhang X-QC. (1980) Chinese J Int Med 19(15).
187. Dilşen N, Koniçe M ve Aral O. (1986) Our diagnostic criteria for Behçet’s disease, Proceedings of the third Mediterranean Congress of Rheumatology 11(15).
188. Mizushima Y. (1988) Recent research into Behçet’s disease., Int J Tiss Reac. 1059-65.
189. Muftuoglu AU, Yazici H, Yurdakul S, Tuzun Y, Pazarli H, Gungen G ve Deniz S. (1986) Behcet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity, Int J Dermatol. 25(4), 235-9.
190. Alpsoy E. (2005) Behcet's disease: treatment of mucocutaneous lesions, Clin Exp Rheumatol. 23(4), 532-9.
191. Akpolat T. (1998) Management of the patient with Behcet's disease, Nephrol Dial Transplant. 13(12), 3002-4.
192. Miyachi Y, Taniguchi S, Ozaki M ve Horio T. (1981) Colchicine in the treatment of the cutaneous manifestations of Behcet's disease, Br J Dermatol. 104(1), 67-9.
193. Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, Saito K ve Sugiura S. (1977) Colchicine in Behcet's disease, Lancet.
2(8046), 1037.
194. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M ve Yazici H. (2001) A double-blind trial of colchicine in Behcet's syndrome, Arthritis Rheum. 44(11), 2686-92.
195. Al-Waiz MM, Sharquie KE, MH. AQ ve Hayani RK. (2005) Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study, Dermatol Online J. 11(3), 3.
196. Kaklamani VG ve Kaklamanis PG. (2001) Treatment of Behcet's disease--an update, Semin Arthritis Rheum. 30(5), 299-312.
197. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M ve Inaba G. (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease, Lancet. 1(8647), 1093-6.
198. Wechsler B, Mertani EB, le Hoang P, de Groc F, Piette JC, Beaufils H, Aupetit B, le Minh H ve Rottembourg J. (1986) Cyclosporin A is effective, but not safe, in the management of Behcet's disease, Arthritis Rheum. 29(4), 574-5.
199. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE ve et al. (1990) A controlled trial of azathioprine in Behcet's syndrome, N Engl J Med. 322(5), 281-5.
200. Yazici H ve Barnes CG. (1991) Practical treatment recommendations for pharmacotherapy of Behcet's syndrome, Drugs. 42(5), 796-804.
201. Bang D. (1997) Treatment of Behcet's disease, Yonsei Med J. 38(6), 401-10.
202. O'Duffy JD, Robertson DM ve Goldstein NP. (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease, Am J Med.
76(1), 75-84.
203. Aoki K ve Sugiura S. (1976) Immunosuppressive treatment of Behcet's disease, Mod Probl Ophthalmol. 16309-13.
204. Zouboulis CC ve Orfanos CE. (1998) Treatment of Adamantiades-Behcet disease with systemic interferon alfa, Arch Dermatol. 134(8), 1010-6.
205. Jorizzo JL, White WL, Wise CM, Zanolli MD ve Sherertz EF. (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions:
cutaneous polyarteritis nodosa and Behcet's disease, J Am Acad Dermatol.
24(6 Pt 1), 973-8.
206. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S ve Markomichelakis N. (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease, Ann Intern Med. 140(5), 404-6.
207. Belpaire FM ve Bogaert MG. (1996) Cytochrome P450: genetic polymorphism and drug interactions, Acta Clin Belg. 51(4), 254-60.
208. Klingenberg M. (1958) Pigments of rat liver microsomes, Arch Biochem Biophys. 75(2), 376-86.
209. Garfinkel D. (1958) Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions, Arch Biochem Biophys. 77(2), 493-509.
210. Omura T ve Sato R. (1962) A new cytochrome in liver microsomes, J Biol Chem. 2371375-6.
211. Omura T ve Sato R. (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. Ii. Solubilization, Purification, and Properties, J Biol Chem.
2392379-85.
212. Omura T ve Sato R. (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature, J Biol Chem. 2392370-8.
213. Estabrook RW, Cooper DY ve Rosenthal O. (1963) The Light Reversible Carbon Monoxide Inhibition of the Steroid C21-Hydroxylase System of the Adrenal Cortex, Biochem Z. 338741-55.
214. Omura T. (1999) Forty years of cytochrome P450, Biochem Biophys Res Commun. 266(3), 690-8.
215. Neve EP ve Ingelman-Sundberg M. (2008) Intracellular transport and localization of microsomal cytochrome P450, Anal Bioanal Chem. 392(6), 1075-84.
216. Seliskar M ve Rozman D. (2007) Mammalian cytochromes P450--importance of tissue specificity, Biochim Biophys Acta. 1770(3), 458-66.
217. Bhupinder SK. (2007) Cytochrome P450 enzyme isoforms and their therapeutic implications: an update, İndian Journal of Medical Sciences.
61(2), 102-116.
218. Estabrook RWH, A. G. Baron, J. Netter, K. J. Leibman, K. (1971) A new spectral intermediate associated with cytochrome P-450 function in liver microsomes, Biochem Biophys Res Commun. 42(1), 132-9.
219. Lewis DF ve Pratt JM. (1998) The P450 catalytic cycle and oxygenation mechanism, Drug Metab Rev. 30(4), 739-86.
220. Gümüs E. (2010) Çocukluk çağında lansoprazolün sitokrom P450 2C19 için fenotipleme belirteci olarak kullanılması ve genotip-fenotip ilişkisinin incelenmesi, 7.
221. Nebert DWA, M. Coon, M. J. Estabrook, R. W. Gonzalez, F. J. Guengerich, F. P. Gunsalus, I. C. Johnson, E. F. Kemper, B. Levin, W. et al.,. (1987) The P450 gene superfamily: recommended nomenclature, DNA. 6(1), 1-11.
222. Nelson DRK, L. Kamataki, T. Stegeman, J. J. Feyereisen, R. Waxman, D. J.
Waterman, M. R. Gotoh, O. Coon, M. J. Estabrook, R. W. Gunsalus, I. C.
Nebert, D. W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics. 6(1), 1-42.
223. Gardiner SJ ve Begg EJ. (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice, Pharmacol Rev. 58(3), 521-90.
224. Kirchheiner J ve Seeringer A. (2007) Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes, Biochim Biophys Acta. 1770(3), 489-94.
225. Nadeau JH. (2002) Single nucleotide polymorphisms: tackling complexity, Nature. 420(6915), 517-8.
226. Sadee W. (1999) Pharmacogenomics, West J Med. 171(5-6), 328-32.
227. Meyer UA. (1991) Genotype or phenotype: the definition of a pharmacogenetic polymorphism, Pharmacogenetics. 1(2), 66-7.
228. Meyer UA ve Zanger UM. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism, Annu Rev Pharmacol Toxicol. 37269-96.
229. Klotz U. (2007) The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications, Clin Pharmacokinet. 46(4), 271-9.
230. Zhou SF. (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, Clin Pharmacokinet. 48(11), 689-723.
231. Ingelman-Sundberg M. (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, Trends Pharmacol Sci. 25(4), 193-200.
232. Phillips KAV, D. L. Oren, E. Lee, J. K. Sadee, W. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review, JAMA. 286(18), 2270-9.
233. Ingelman-Sundberg M. (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy, J Intern Med. 250(3), 186-200.
234. Nebert DW ve Russell DW. (2002) Clinical importance of the cytochromes P450, Lancet. 360(9340), 1155-62.
235. Romkes MF, M. B. Blaisdell, J. A. Raucy, J. L. Goldstein, J. A. (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily, Biochemistry. 30(13), 3247-55.
236. Goldstein JA ve de Morais SM. (1994) Biochemistry and molecular biology of the human CYP2C subfamily, Pharmacogenetics. 4(6), 285-99.
237. Wada YM, M. Ishihara, Y. Watanabe, M. Iwasaki, M. Asahi, S. (2008) Important amino acid residues that confer CYP2C19 selective activity to CYP2C9, J Biochem. 144(3), 323-33.
238. Goldstein JA. (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br J Clin Pharmacol. 52(4), 349-55.
239. Ablin J, Cabili S, Eldor A, Lagziel A ve Peretz H. (2004) Warfarin therapy is feasible in CYP2C9*3 homozygous patients, Eur J Intern Med. 15(1), 22-27.
240. Gotoh O. (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences, J Biol Chem. 267(1), 83-90.
241. Yasar U. (2002) Cytochrome P450 2C9 polymorphism: Interindividual differences in drug metabolism and phenotyping methodology, 22.
242. Wang BW, J. Huang, S. Q. Su, H. H. Zhou, S. F. (2009) Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance, Curr Drug Metab. 10(7), 781-834.
243. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Nacak M ve Roots I. (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin, Br J Clin Pharmacol. 48(3), 409-15.
244. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A. (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population, Eur J Clin Pharmacol. 60(5), 337-42.
245. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U. (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans, Clin Pharmacol Ther. 76(2), 113-8.
246. Crespi CL ve Miller VP. (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase, Pharmacogenetics. 7(3), 203-10.
247. Aithal GP, Day CP, Kesteven PJ ve Daly AK. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet. 353(9154), 717-9.
248. Furuya HF-S, P. Gregory, W. Taber, H. Steward, A. Gonzalez, F. J. Idle, J.
R. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy, Pharmacogenetics. 5(6), 389-92.
249. Timmermans PBW, P. C. Chiu, A. T. Herblin, W. F. Benfield, P. Carini, D. J.
Lee, R. J. Wexler, R. R. Saye, J. A. Smith, R. D. (1993) Angiotensin II receptors and angiotensin II receptor antagonists, Pharmacol Rev. 45(2), 205-51.
250. Stearns RAC, P. K. Chen, R. Chiu, S. H. (1995) Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes.
Role of cytochrome P4502C and 3A subfamily members, Drug Metab Dispos. 23(2), 207-15.
251. Lo MWG, M. R. McCrea, J. B. Lu, H. Furtek, C. I. Bjornsson, T. D. (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans, Clin Pharmacol Ther. 58(6), 641-9.
252. Yang SHC, Y. A. Choi, J. S. (2011) Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats, Acta Pharmacol Sin. 32(7), 967-72.
253. Yasar UT, G. Hidestrand, M. Oscarson, M. Ingelman-Sundberg, M. Dahl, M.
L. Eliasson, E. (2001) Role of CYP2C9 polymorphism in losartan oxidation, Drug Metab Dispos. 29(7), 1051-6.
254. Munafo AC, Y. Nussberger, J. Shum, L. Y. Borland, R. M. Lee, R. J. Waeber, B. Biollaz, J. Brunner, H. R. (1992) Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist, Clin Pharmacol Ther. 51(5), 513-21.
255. Kazierad DJM, D. E. Blum, R. A. Tenero, D. M. Ilson, B. Boike, S. C.
Etheredge, R. Jorkasky, D. K. (1997) Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers, Clin Pharmacol Ther. 62(4), 417-25.
256. Kaukonen KM, Olkkola KT ve Neuvonen PJ. (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174, Eur J Clin Pharmacol. 53(6), 445-9.
257. Sica DA, Gehr TW ve Ghosh S. (2005) Clinical pharmacokinetics of losartan, Clin Pharmacokinet. 44(8), 797-814.
258. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist, F. Eliasson, E. Dahl, M. L. (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype, Clin Pharmacol Ther.
71(1), 89-98.
259. Yasar U, Babaoglu MO ve Bozkurt A. (2008) Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1), Basic Clin Pharmacol Toxicol. 103(2), 176-9.
260. Gunes AC, U. Boruban, C. Gunel, N. Babaoglu, M. O. Sencan, O. Bozkurt, A. Rane, A. Hassan, M. Zengil, H. Yasar, U. (2006) Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients, Basic Clin Pharmacol Toxicol. 98(2), 197-200.
261. Gunes A, Bilir E, Zengil H, Babaoglu MO, Bozkurt A ve Yasar U. (2007) Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients, Basic Clin Pharmacol Toxicol. 100(6), 383-6.
262. Mahgoub A, Idle JR, Dring LG, Lancaster R ve Smith RL. (1977) Polymorphic hydroxylation of Debrisoquine in man, Lancet. 2(8038), 584-6.
263. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR ve Smith RL.
(1979) Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians, Clin Pharmacol Ther. 26(5), 584-91.
264. Eichelbaum M, Spannbrucker N ve Dengler HJ. (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics, Eur J Clin Pharmacol. 16(3), 189-94.
265. Eichelbaum M, Spannbrucker N, Steincke B ve Dengler HJ. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect, Eur J Clin Pharmacol. 16(3), 183-7.
266. Kupfer A ve Preisig R. (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man, Eur J Clin Pharmacol. 26(6), 753-9.
267. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR ve Branch RA. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin Pharmacol Ther. 38(4), 402-8.
268. Wrighton SA, Stevens JC, Becker GW ve VandenBranden M. (1993) Isolation and characterization of human liver cytochrome P450 2C19:
correlation between 2C19 and S-mephenytoin 4'-hydroxylation, Arch Biochem Biophys. 306(1), 240-5.
269. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM ve Ghanayem BI. (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans, Biochemistry. 33(7), 1743-52.
270. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA ve Goldstein JA. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem.
269(22), 15419-22.
271. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K ve Goldstein JA. (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese, Mol Pharmacol.
46(4), 594-8.
272. Wedlund PJ. (2000) The CYP2C19 enzyme polymorphism, Pharmacology.
61(3), 174-83.
273. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P ve Goldstein JA. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin, J Pharmacol Exp Ther.
284(1), 356-61.
274. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM ve Evans DA. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations, Pharmacogenetics. 7(1), 59-64.
275. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, Kayaalp SO, Roots I ve Brockmoller J. (1999) Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population, Clin Pharmacol Ther. 66(2), 185-92.
276. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A ve Kayaalp SO. (1996) Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population, Br J Clin Pharmacol. 42(6), 771-3.
277. deMorais SMF, Goldstein JA ve Xie HG. (1995) Genetic analysis of the Smephenytoin polymorphism in a Chinese population, Clin Pharmacol Ther.
58, 404-411.
278. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN ve Bertilsson L. (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population, Pharmacogenetics. 6(5), 441-7.
279. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN ve Bertilsson L. (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population, Pharmacogenetics. 6(6), 547-51.
280. Kimura M, Ieiri I, Mamiya K, Urae A ve Higuchi S. (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population, Ther Drug Monit. 20(3), 243-7.
281. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, Satyanarayanamoorthy K, Peter A ve Rajagopal K. (2005) CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population, Fundam Clin Pharmacol. 19(1), 101-5.
282. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS ve Brosen K. (2005) Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population, Eur J Clin Pharmacol. 61(7), 491-7.
283. Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ ve Benitez J.
(1993) Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations, Eur J Clin Pharmacol.
44(6), 593-5.
284. Marandi T, Dahl ML, Kiivet RA, Rago L ve Sjoqvist F. (1996) Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population, Pharmacol Toxicol. 78(5), 303-7.
285. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH ve Zhou HH. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele, J Pharmacol Exp Ther. 281(1), 604-9.
286. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI ve Blaisdell J. (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin, J Pharmacol Exp Ther. 286(3), 1490-5.
287. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B ve Goldstein JA. (2002) Identification and functional
characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. 12(9), 703-11.
288. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L ve Ingelman-Sundberg M. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther. 79(1), 103-13.
289. Rudberg I, Mohebi B, Hermann M, Refsum H ve Molden E. (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients, Clin Pharmacol Ther. 83(2), 322-7.
290. Rosemary J ve Adithan C. (2007) The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance, Curr Clin Pharmacol.
2(1), 93-109.
291. Saitoh T, Otsuka H, Kawasaki T, Endo H, Iga D, Tomimatsu M, Fukushima Y, Katsube T, Ogawa K ve Otsuka K. (2009) Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy, Hepatogastroenterology. 56(91-92), 703-6.
292. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T ve Hanai H. (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole, Clin Pharmacol Ther. 72(4), 453-60.
293. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K ve Ishizaki T. (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status, Clin Pharmacol Ther. 76(4), 290-301.
294. Yang JC ve Lin CJ. (2010) CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection, Expert Opin Drug Metab Toxicol.
6(1), 29-41.
295. Desta Z, Soukhova NV ve Flockhart DA. (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A, Antimicrob Agents Chemother. 45(2), 382-92.
296. Zaigler M, Tantcheva-Poor I ve Fuhr U. (2000) Problems and perspectives of phenotyping for drug-metabolizing enzymes in man, Int J Clin Pharmacol Ther. 38(1), 1-9.
297. Kupfer A, Roberts RK, Schenker S ve Branch RA. (1981) Stereoselective metabolism of mephenytoin in man, J Pharmacol Exp Ther. 218(1), 193-9.
298. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Touw DJ, de Zeeuw RA, de Leij LF ve Jonkman JH. (2001) Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events, Br J Clin Pharmacol. 51(5), 471-4.